

ENSAYOS CLÍNICOS TUMORES GENITOURINARIO

- UROTELIO/VEJIGA

MK3475-676

“Ensayo de fase 3 de BCG con o sin pembrolizumab para el cáncer de vejiga sin invasión muscular de alto riesgo (KEYNOTE-676)”

<https://clinicaltrials.gov/ct2/show/NCT03711032?term=MK3475-676&rank=1>

SGNDV-001

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination With Pembrolizumab Versus Chemotherapy in Subjects With Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (IHC 1+ and Greater)

<https://clinicaltrials.gov/study/NCT05911295?term=SGNDV-001&rank=1>

BICYCLE: BT8009-230

A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

<https://clinicaltrials.gov/study/NCT06225596?term=BT8009-230&rank=1>

- C.RENAL

XL092-304

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

<https://clinicaltrials.gov/study/NCT05678673?term=XL092-304&rank=1>

- C.PRÓSTATA

MK3475-365

“Ensayo de fase Ib/II de tratamientos combinados con pembrolizumab (MK-3475) en el cáncer de próstata resistente a la castración metastásico (CPRCm) (KEYNOTE-365) “

<https://clinicaltrials.gov/ct2/show/NCT02861573?term=MK3475-365&rank=1>



Hospital General Universitario
Gregorio Marañón

 Comunidad de Madrid



-C.ENDOMETRIO

ART0380C001

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

<https://clinicaltrials.gov/ct2/show/NCT04657068?term=ART0380&draw=2&rank=1>